Cocrystal Pharma, Inc.
COCP
$1.04
$0.032.97%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -70.57% | -73.96% | -53.90% | -52.26% | -22.70% |
| Gross Profit | 70.57% | 73.96% | 53.90% | 52.26% | 22.70% |
| SG&A Expenses | -36.94% | -13.51% | -18.79% | -14.72% | -2.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -58.57% | -61.31% | -43.70% | -42.99% | -16.56% |
| Operating Income | 58.57% | 61.31% | 43.70% | 42.99% | 16.56% |
| Income Before Tax | 58.51% | 61.54% | 41.84% | 26.84% | -18.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 58.51% | 61.54% | 41.84% | 26.84% | -18.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.51% | 61.54% | 41.84% | 26.84% | -18.58% |
| EBIT | 58.57% | 61.31% | 43.70% | 42.99% | 16.56% |
| EBITDA | 58.58% | 61.46% | 43.83% | 43.09% | 16.33% |
| EPS Basic | 61.61% | 61.54% | 41.82% | 26.49% | -18.36% |
| Normalized Basic EPS | 61.60% | 61.55% | 41.81% | 39.96% | 14.51% |
| EPS Diluted | 61.61% | 61.54% | 41.82% | 26.49% | -18.36% |
| Normalized Diluted EPS | 61.60% | 61.55% | 41.81% | 39.96% | 14.51% |
| Average Basic Shares Outstanding | 8.03% | 0.00% | 0.00% | -0.46% | 0.21% |
| Average Diluted Shares Outstanding | 8.03% | 0.00% | 0.00% | -0.46% | 0.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |